Feed VCYT
VC

Veracyte VCYT · NASDAQ

$43.80 +1.58% (+$0.68)

Market cap
$3.52B
Enterprise value
$3.26B
P/E
30.8x
Forward P/E
23.0x
PEG
0.3x
P/S
6.3x
P/FCF
21.3x
EV/EBITDA
25.1x
ROIC
7.0%
Gross margin
72.1%
Net margin
20.4%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-2.0x
Beta
1.95
Free float
99.4%

About the company

Veracyte, Inc. is an American biotechnology company specializing in diagnostics and predictive testing using advanced genomic technologies. The company develops and commercializes tests for the diagnosis and monitoring of various types of cancer and other diseases, such as lung cancer, thyroid cancer, and pulmonary fibrosis. Veracyte focuses on improving diagnostic accuracy and personalizing treatment for patients through non-invasive tests that assist healthcare providers in selecting the most appropriate therapeutic approach.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Marc Stapley

Employees

755

Headquarters

South San Francisco

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.